Ibex Medical Analytics, with headquarters in Tel Aviv and Brookline, Mass., is touting continued global expansion and a leadership transition. Altogether, Ibex said, these moves underscore a global shift toward AI-powered pathology as a new gold standard for cancer detection.

Ibex Celebrates Milestones

The company said commercial milestones—namely strategically relevant clinical developments—were recently achieved with two of Europe’s largest laboratory networks. Other benchmarks were hit with PathGroup and HNL Lab Medicine in the U.S.

Additionally, customers such as Fimlab of Finland built on their existing partnerships with Ibex. The total number of cases running through Ibex’s platform doubled for a second straight year. The company also grew its customer base by 70%.

Its number of new applications running live in 2025 were more than three times that of 2024.

On the personnel side, Ibex announced two major moves. Yair Heller, previously the company’s Chief Operating Officer, is now Chief Executive Officer. Co-founder Joseph Mossel, meanwhile, will lead the expansion of Ibex’s biopharma division.

Medical Analytics Moving Forward

Part of this expansion, within the life sciences realm, involves Ibex enhancing its platform to support drug development. It aims to do this throughout the entire lifecycle—from biomarker assessment and clinical trial optimization up through regulatory clearance.

The final step, of course, is clinical deployment. To that end, Mossel will also oversee clinical growth initiatives within the U.S.

“I am thrilled to now focus my energy on our growing biopharma business,” Mossel said. “We have a unique opportunity to help bring life-saving treatments to market faster.”

“[Ibex] is entering 2026 with tremendous momentum and a clear path to scaling our platform globally,” Heller said. “As we scale, we will continue delivering the most accurate and reliable tools for pathologists to help improve patient care.”